Smoking Cessation Drugs: World Market Prospects 2012-2022
Why the smoking treatment market can grow - discover its potential now
What are the commercial prospects for anti-smoking treatments? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.
Our investigation gives you business research and analysis with sales forecasts. It lets you assess forecasted sales at world market, submarket, product and national level to 2022.
You find analysis of prescription (Rx) and over-the-counter (OTC) therapies for smoking. How will leading products - including Nicorette, Nicotinell and Champix/Chantix - perform from 2012? Our report gives predictions and discussions of sales potential.
Also, you see forecasting of therapeutic categories to 2022, finding potential revenues:
Innovations in drug delivery and rising demand in developing countries will also stimulate the industry and market. The study shows you technological and commercial possibilities.
What about leading companies? Our work discusses Pfizer, GSK, Novartis and other players. You see where companies are heading from 2012.
You can investigate the future of medicine for smoking cessation now, finding revenue potentials and other trends.
Sales forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussion of R&D activities. You receive 34 tables, 29 charts and three research interviews.
Eight ways Smoking Cessation Drugs: World Market Prospects 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
Without our report, you could miss information that your competitors are using.
Gain business research and analysis now for anti-smoking medications
Our study is for everybody needing industry and market analyses for treatments to stop smoking. You find data, trends and answers there. Please order that report now.
What are the commercial prospects for anti-smoking treatments? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.
Our investigation gives you business research and analysis with sales forecasts. It lets you assess forecasted sales at world market, submarket, product and national level to 2022.
You find analysis of prescription (Rx) and over-the-counter (OTC) therapies for smoking. How will leading products - including Nicorette, Nicotinell and Champix/Chantix - perform from 2012? Our report gives predictions and discussions of sales potential.
Also, you see forecasting of therapeutic categories to 2022, finding potential revenues:
- Over-the-counter (OTC) smoking cessation products
- Prescription (Rx) drugs
- Nicotine replacement therapy (NRT)
- Nicotine receptor partial agonists
- Antidepressant therapy segment.
- Nicotine vaccines
- Monoamine oxidase inhibitors
- Cannabinoid receptor-1 antagonists
- Dopamine D3 antagonists
- Opiate antagonists
- Other agents for smoking therapy.
Innovations in drug delivery and rising demand in developing countries will also stimulate the industry and market. The study shows you technological and commercial possibilities.
What about leading companies? Our work discusses Pfizer, GSK, Novartis and other players. You see where companies are heading from 2012.
You can investigate the future of medicine for smoking cessation now, finding revenue potentials and other trends.
Sales forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussion of R&D activities. You receive 34 tables, 29 charts and three research interviews.
Eight ways Smoking Cessation Drugs: World Market Prospects 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
- Find potential revenues to 2022 for the world market and submarkets
- Discover projected revenue trends of leading products to 2022
- See market forecasting to 2022 for the US, Japan, EU5, China and India
- Assess leading companies, discovering activities and outlooks
- Review R&D, seeing pipeline trends by therapeutic area
- Investigate competition and opportunities influencing sales
- Find out what will stimulate and restrain the industry and market
- View opinion from our survey, seeing interviews with authorities.
Without our report, you could miss information that your competitors are using.
Gain business research and analysis now for anti-smoking medications
Our study is for everybody needing industry and market analyses for treatments to stop smoking. You find data, trends and answers there. Please order that report now.
1. EXECUTIVE SUMMARY
1.1 Smoking Cessation Drugs: World Market Overview
1.2 Aims and Format of the Report
1.3 Research and Analysis Methods
1.4 Scope of the Report
2. INTRODUCTION TO SMOKING CESSATION
2.1 Tobacco
2.1.1 Types of Tobacco Consumption
2.1.2 Tobacco Smoking is a Major Challenge for Healthcare Worldwide
2.2 Smoking-Related Health Disorders
2.3 Nicotine Addiction
2.4 Smoking Cessation
2.4.1 Why is it Difficult to Stop Smoking?
2.4.2 Methods for Smoking Cessation
3. WORLD SMOKING CESSATION DRUGS MARKET TO 2022
3.1 Smoking Cessation Drugs Market by Use
3.1.1 Over-the-Counter (OTC) Smoking Cessation Drugs, 2010
3.1.1.1 OTC Smoking Cessation Drugs: Forecast, 2012-2022
3.1.2 Prescription (Rx) Smoking Cessation Drugs, 2010
3.1.2.1 Prescription Smoking Cessation Drugs: Forecast, 2012-2022
3.2 Smoking Cessation Drugs by Mechanism of Action
3.2.1 Nicotine Replacement Therapy
3.2.1.1 Nicotine Replacement Therapy, 2010
3.2.1.2 Nicotine Replacement Therapy Forecast, 2012-2022
3.2.2 Nicotine Receptor Partial Agonist Drugs
3.2.2.1 Nicotine Receptor Partial Agonist Drugs, 2010
3.2.2.2 Nicotine Receptor Partial Agonist Drugs Forecast, 2012-2022
3.2.3 Antidepressants
3.2.3.1 Antidepressants for Smoking Cessation, 2010
3.2.3.2 Antidepressants for Smoking Cessation: Forecast, 2012-2022
4. LEADING NATIONAL MARKETS FOR SMOKING CESSATION DRUGS TO 2022
4.1 The Leading Smoking Cessation Markets, 2010
4.2 The US Smoking Cessation Market
4.2.1 Smoking Prevalence Declining in US
4.2.2 Availability and Reimbursement of Smoking Cessation Aids in the US
4.2.3 US Smoking Cessation Market Revenue, 2010
4.2.4 US Smoking Cessation Market Forecast, 2012-2022
4.2.5 Scope for US Smoking Cessation Market Expansion
4.3 The Japanese Smoking Cessation Market
4.3.1 Japan has a Less Developed Smoking Cessation Market
4.3.2 The Japanese Smoking Cessation Market, 2010
4.3.3 Japanese Smoking Cessation Market Forecast, 2012-2022
4.4 The Top 5 EU Smoking Cessation Markets (EU5 Countries)
4.4.1 The UK Smoking Cessation Market
4.4.1.1 Tobacco Use in the UK
4.4.1.2 The UK Pioneers Smoking Cessation Reimbursement and General Sales OTC Retailing of NRT
4.4.1.3 The UK is Europe's Largest Smoking Cessation Market
4.4.1.4 UK Government Anti-Smoking Legislation Lifts Market
4.4.1.5 UK Smoking Cessation Market, 2010
4.4.1.6 UK Smoking Cessation Market Forecast, 2012-2022
4.4.2 The French Smoking Cessation Market
4.4.2.1 French Smoking Prevalence
4.4.2.2 The French Smoking Cessation Market, 2010
4.4.2.3 French Government's Provision of Smoking Cessation Aid Reimbursement
4.4.2.4 French Smoking Cessation Market Forecast, 2012-2022
4.4.3 The Spanish Smoking Cessation Market
4.4.3.1 Smoking Bans in Spain
4.4.3.2 The Spanish Smoking Cessation Market, 2010
4.4.3.3 The Spanish Smoking Cessation Market Forecast, 2012-2022
4.4.4 The Italian Smoking Cessation Market
4.4.4.1 Smoking Bans in Italy
4.4.4.2 The Italian Smoking Cessation Market, 2010
4.4.4.3 The Italian Smoking Cessation Market Forecast, 2012-2022
4.4.5 The German Smoking Cessation Market
4.4.5.1 The German Smoking Cessation Market, 2010
4.4.5.2 Factors Holding Back the German Smoking Cessation Market
4.4.5.3 German Smoking Cessation Market Forecast, 2012-2022
4.5 The Chinese Smoking Cessation Market
4.5.1 More than 5 Billion Cigarettes are Smoked in China Every Day
4.5.2 The Chinese Smoking Cessation Market, 2010
4.5.3 The Chinese Smoking Cessation Market is Under Developed
4.5.4 Smoking Cessation Market Prospects in China
4.5.5 Chinese Smoking Cessation Market Forecast, 2012-2022
4.6 The Indian Smoking Cessation Market
4.6.1 Tobacco Use in India
4.6.2 The Indian Smoking Cessation Market, 2010
4.6.3 Indian Smoking Cessation Market Still in its Infancy
4.6.4 Prospects for Growth of the Indian Smoking Cessation Market
4.6.5 Indian Smoking Cessation Market Forecast, 2012-2022
5. LEADING SMOKING CESSATION PRODUCTS: OUTLOOK TO 2022
5.1 The Top 5 Brands Claimed Most of the Market in 2010
5.2 Nicotine Replacement Therapy
5.2.1 NiQuitin/Nicabate/NicoDerm CQ (GSK)
5.2.1.1 NiQuitin/Nicabate/NicoDerm CQ Sales, 2010
5.2.1.2 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast, 2012-2022
5.2.2 Nicorette (Johnson & Johnson/Takeda/Perrigo Company)
5.2.2.1 Nicorette Sales, 2010
5.2.2.2 Nicorette Sales Forecast, 2012-2022
5.2.3 Nicotinell (Novartis)
5.2.3.1 Nicotinell Sales, 2010
5.2.3.2 Nicotinell Sales Forecast, 2012-2022
5.2.4 Other NRT Products
5.3 Champix/Chantix (Varenicline, Pfizer)
5.3.1 Champix/Chantix Sales, 2010
5.3.2 Champix/Chantix Sales Forecast, 2012-2022
5.3.3 Champix/Chantix May Help in Treating Alcohol Addiction
5.4 Zyban (Bupropion, GSK)
5.4.1 Zyban Sales, 2010
5.4.2 Zyban Sales Forecast, 2012-2022
5.5 Summary of Leading Smoking Cessation Brands, 2010
5.6 Other Smoking Cessation Aids
5.6.1 Smokeless Tobacco
5.6.1.1 E-Cigarettes
5.6.1.2 Snus/Snuff
5.6.1.3 Gutkhas
5.6.2 CigRx Dietary Supplement
5.6.3 Dissolvable Tobacco
5.6.4 Behavioural Therapy
6. SMOKING CESSATION R&D PIPELINE ANALYSIS
6.1 Nicotine Vaccines: Hype or Hope?
6.1.1 NicVAX (Nabi Biopharmaceuticals)
6.1.2 CYT002-NicQb (Cytos Biotechnology/Novartis)
6.1.3 TA-Nic (Celtic Pharma)
6.1.4 Niccine (Independent Pharmaceutica AB)
6.1.5 SEL-068 (Selecta Biosciences)
6.2 Monoamine Oxidase Inhibitors
6.2.1 EVT 302 (Evotec/Roche)
6.2.2 Selegiline (NIDA)
6.3 Cannabinoid Receptor-1 Antagonists
6.3.1 Rimonabant (Sanofi)
6.4 Dopamine D3 Antagonists
6.4.1 GSK598809 (GSK)
6.5 Opiate Antagonists
6.5.1 Naltrexone (Alkermes/Cephalon)
6.6 ARD-1600 (Aradigm)
6.7 EMB-001(Embera NeuroTherapeutics)
6.8 Meclizine (Duke University/Philip Morris Products)
6.9 Other Smoking Cessation Aids Under Development
6.9.1 X22TM (22nd Century Group)
6.9.2 Other Developments
7. SMOKING CESSATION INDUSTRY AND MARKET: QUALITATIVE ANALYSES
7.1 Strengths of the Smoking Cessation Industry
7.1.1 Innovation in Smoking Cessation Therapies
7.1.2 Innovative Marketing
7.1.3 Support Plans and Web 2.0 Technology in Combination with Pharmacotherapy
7.1.4 OTC Switching
7.2 Weaknesses of the Smoking Cessation Industry
7.2.1 Drugs Do Not Replace the Tactile and Oral Sensations Obtained from Smoking
7.2.2 Currently-Marketed Smoking Cessation Therapies - Relapse Rate
7.3 Opportunities for the Smoking Cessation Industry
7.3.1 Smoking is Prevalent Worldwide and Slowly Increasing
7.3.2 Countries with Untapped Smoking Cessation Market Potential
7.3.3 Growth of Emerging-Economy Smoking Cessation Markets
7.3.4 Health Effects of Tobacco
7.3.5 Economic Impact of Tobacco on Society
7.3.6 Framework Convention on Tobacco Control (FCTC)
7.3.7 Government-Sponsored Smoking Cessation Programmes
7.3.8 Increasing Tobacco Taxes
7.3.9 Smoking Bans
7.3.10 Warning Information on Tobacco Products
7.3.11 Bans on Tobacco Advertising, Promotion and Sponsorship
7.4 Threats to the Smoking Cessation Industry
7.4.1 Concern over Side-Effects of Smoking Cessation Drugs
7.4.1.1 Champix/Chantix
7.4.1.2 Side-Effect Concerns for NRT and Bupropion
7.4.1.3 The Result of Side-Effect Concerns
7.4.2 Lack of Reimbursement for Smoking Cessation Therapies
7.4.3 Traditional Smokeless Tobacco
7.4.3.1 Snus and Gutkha
7.4.3.2 Possible Impact of Greater Smokeless Tobacco Use
7.4.4 The E-Cigarette
7.4.4.1 The E-Cigarette Market
7.4.4.2 Will E-Cigarettes Replace Smoking and Threaten the Smoking Cessation Drug Market?
7.4.4.3 E-Cigarettes and Smoking Cessation Therapies
8. RESEARCH INTERVIEWS
8.1 Interview with Dr Raafat Fahim, CEO, Nabi Biopharmaceuticals
8.1.1 Nicotine Vaccines
8.1.2 Smoking Cessation R&D Pipeline
8.1.3 Major Areas of Focus
8.1.4 Unmet Needs
8.1.5 Opportunities for Revenue Growth
8.2 Interview with Mr Trevor Van Meirlo, CEO, EvolutionNHS
8.2.1 Unmet Needs
8.2.2 Major Areas of Focus
8.2.3 Smoking Cessation R&D Pipeline
8.2.4 Opportunities for Revenue Growth
8.2.5 Market Drivers
8.3 Interview with Dr Peter Hajek, Director of Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
8.3.1 Unmet Needs
8.3.2 Major Areas of Focus and R&D Pipeline
8.3.3 Opportunities for Revenue Growth
8.3.4 Market Drivers
9. CONCLUSIONS OF THE STUDY
9.1 Smoking is the Main Cause of Preventable Deaths Worldwide
9.2 Smoking Cessation Medicines Have Promising Therapeutic and Commercial Potential from 2012 to 2022
9.3 World Smoking Cessation Market: Prospects to 2022
9.4 Market Drivers
9.5 Leading and Emerging Smoking Cessation Markets
9.6 Concluding Remarks
1.1 Smoking Cessation Drugs: World Market Overview
1.2 Aims and Format of the Report
1.3 Research and Analysis Methods
1.4 Scope of the Report
2. INTRODUCTION TO SMOKING CESSATION
2.1 Tobacco
2.1.1 Types of Tobacco Consumption
2.1.2 Tobacco Smoking is a Major Challenge for Healthcare Worldwide
2.2 Smoking-Related Health Disorders
2.3 Nicotine Addiction
2.4 Smoking Cessation
2.4.1 Why is it Difficult to Stop Smoking?
2.4.2 Methods for Smoking Cessation
3. WORLD SMOKING CESSATION DRUGS MARKET TO 2022
3.1 Smoking Cessation Drugs Market by Use
3.1.1 Over-the-Counter (OTC) Smoking Cessation Drugs, 2010
3.1.1.1 OTC Smoking Cessation Drugs: Forecast, 2012-2022
3.1.2 Prescription (Rx) Smoking Cessation Drugs, 2010
3.1.2.1 Prescription Smoking Cessation Drugs: Forecast, 2012-2022
3.2 Smoking Cessation Drugs by Mechanism of Action
3.2.1 Nicotine Replacement Therapy
3.2.1.1 Nicotine Replacement Therapy, 2010
3.2.1.2 Nicotine Replacement Therapy Forecast, 2012-2022
3.2.2 Nicotine Receptor Partial Agonist Drugs
3.2.2.1 Nicotine Receptor Partial Agonist Drugs, 2010
3.2.2.2 Nicotine Receptor Partial Agonist Drugs Forecast, 2012-2022
3.2.3 Antidepressants
3.2.3.1 Antidepressants for Smoking Cessation, 2010
3.2.3.2 Antidepressants for Smoking Cessation: Forecast, 2012-2022
4. LEADING NATIONAL MARKETS FOR SMOKING CESSATION DRUGS TO 2022
4.1 The Leading Smoking Cessation Markets, 2010
4.2 The US Smoking Cessation Market
4.2.1 Smoking Prevalence Declining in US
4.2.2 Availability and Reimbursement of Smoking Cessation Aids in the US
4.2.3 US Smoking Cessation Market Revenue, 2010
4.2.4 US Smoking Cessation Market Forecast, 2012-2022
4.2.5 Scope for US Smoking Cessation Market Expansion
4.3 The Japanese Smoking Cessation Market
4.3.1 Japan has a Less Developed Smoking Cessation Market
4.3.2 The Japanese Smoking Cessation Market, 2010
4.3.3 Japanese Smoking Cessation Market Forecast, 2012-2022
4.4 The Top 5 EU Smoking Cessation Markets (EU5 Countries)
4.4.1 The UK Smoking Cessation Market
4.4.1.1 Tobacco Use in the UK
4.4.1.2 The UK Pioneers Smoking Cessation Reimbursement and General Sales OTC Retailing of NRT
4.4.1.3 The UK is Europe's Largest Smoking Cessation Market
4.4.1.4 UK Government Anti-Smoking Legislation Lifts Market
4.4.1.5 UK Smoking Cessation Market, 2010
4.4.1.6 UK Smoking Cessation Market Forecast, 2012-2022
4.4.2 The French Smoking Cessation Market
4.4.2.1 French Smoking Prevalence
4.4.2.2 The French Smoking Cessation Market, 2010
4.4.2.3 French Government's Provision of Smoking Cessation Aid Reimbursement
4.4.2.4 French Smoking Cessation Market Forecast, 2012-2022
4.4.3 The Spanish Smoking Cessation Market
4.4.3.1 Smoking Bans in Spain
4.4.3.2 The Spanish Smoking Cessation Market, 2010
4.4.3.3 The Spanish Smoking Cessation Market Forecast, 2012-2022
4.4.4 The Italian Smoking Cessation Market
4.4.4.1 Smoking Bans in Italy
4.4.4.2 The Italian Smoking Cessation Market, 2010
4.4.4.3 The Italian Smoking Cessation Market Forecast, 2012-2022
4.4.5 The German Smoking Cessation Market
4.4.5.1 The German Smoking Cessation Market, 2010
4.4.5.2 Factors Holding Back the German Smoking Cessation Market
4.4.5.3 German Smoking Cessation Market Forecast, 2012-2022
4.5 The Chinese Smoking Cessation Market
4.5.1 More than 5 Billion Cigarettes are Smoked in China Every Day
4.5.2 The Chinese Smoking Cessation Market, 2010
4.5.3 The Chinese Smoking Cessation Market is Under Developed
4.5.4 Smoking Cessation Market Prospects in China
4.5.5 Chinese Smoking Cessation Market Forecast, 2012-2022
4.6 The Indian Smoking Cessation Market
4.6.1 Tobacco Use in India
4.6.2 The Indian Smoking Cessation Market, 2010
4.6.3 Indian Smoking Cessation Market Still in its Infancy
4.6.4 Prospects for Growth of the Indian Smoking Cessation Market
4.6.5 Indian Smoking Cessation Market Forecast, 2012-2022
5. LEADING SMOKING CESSATION PRODUCTS: OUTLOOK TO 2022
5.1 The Top 5 Brands Claimed Most of the Market in 2010
5.2 Nicotine Replacement Therapy
5.2.1 NiQuitin/Nicabate/NicoDerm CQ (GSK)
5.2.1.1 NiQuitin/Nicabate/NicoDerm CQ Sales, 2010
5.2.1.2 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast, 2012-2022
5.2.2 Nicorette (Johnson & Johnson/Takeda/Perrigo Company)
5.2.2.1 Nicorette Sales, 2010
5.2.2.2 Nicorette Sales Forecast, 2012-2022
5.2.3 Nicotinell (Novartis)
5.2.3.1 Nicotinell Sales, 2010
5.2.3.2 Nicotinell Sales Forecast, 2012-2022
5.2.4 Other NRT Products
5.3 Champix/Chantix (Varenicline, Pfizer)
5.3.1 Champix/Chantix Sales, 2010
5.3.2 Champix/Chantix Sales Forecast, 2012-2022
5.3.3 Champix/Chantix May Help in Treating Alcohol Addiction
5.4 Zyban (Bupropion, GSK)
5.4.1 Zyban Sales, 2010
5.4.2 Zyban Sales Forecast, 2012-2022
5.5 Summary of Leading Smoking Cessation Brands, 2010
5.6 Other Smoking Cessation Aids
5.6.1 Smokeless Tobacco
5.6.1.1 E-Cigarettes
5.6.1.2 Snus/Snuff
5.6.1.3 Gutkhas
5.6.2 CigRx Dietary Supplement
5.6.3 Dissolvable Tobacco
5.6.4 Behavioural Therapy
6. SMOKING CESSATION R&D PIPELINE ANALYSIS
6.1 Nicotine Vaccines: Hype or Hope?
6.1.1 NicVAX (Nabi Biopharmaceuticals)
6.1.2 CYT002-NicQb (Cytos Biotechnology/Novartis)
6.1.3 TA-Nic (Celtic Pharma)
6.1.4 Niccine (Independent Pharmaceutica AB)
6.1.5 SEL-068 (Selecta Biosciences)
6.2 Monoamine Oxidase Inhibitors
6.2.1 EVT 302 (Evotec/Roche)
6.2.2 Selegiline (NIDA)
6.3 Cannabinoid Receptor-1 Antagonists
6.3.1 Rimonabant (Sanofi)
6.4 Dopamine D3 Antagonists
6.4.1 GSK598809 (GSK)
6.5 Opiate Antagonists
6.5.1 Naltrexone (Alkermes/Cephalon)
6.6 ARD-1600 (Aradigm)
6.7 EMB-001(Embera NeuroTherapeutics)
6.8 Meclizine (Duke University/Philip Morris Products)
6.9 Other Smoking Cessation Aids Under Development
6.9.1 X22TM (22nd Century Group)
6.9.2 Other Developments
7. SMOKING CESSATION INDUSTRY AND MARKET: QUALITATIVE ANALYSES
7.1 Strengths of the Smoking Cessation Industry
7.1.1 Innovation in Smoking Cessation Therapies
7.1.2 Innovative Marketing
7.1.3 Support Plans and Web 2.0 Technology in Combination with Pharmacotherapy
7.1.4 OTC Switching
7.2 Weaknesses of the Smoking Cessation Industry
7.2.1 Drugs Do Not Replace the Tactile and Oral Sensations Obtained from Smoking
7.2.2 Currently-Marketed Smoking Cessation Therapies - Relapse Rate
7.3 Opportunities for the Smoking Cessation Industry
7.3.1 Smoking is Prevalent Worldwide and Slowly Increasing
7.3.2 Countries with Untapped Smoking Cessation Market Potential
7.3.3 Growth of Emerging-Economy Smoking Cessation Markets
7.3.4 Health Effects of Tobacco
7.3.5 Economic Impact of Tobacco on Society
7.3.6 Framework Convention on Tobacco Control (FCTC)
7.3.7 Government-Sponsored Smoking Cessation Programmes
7.3.8 Increasing Tobacco Taxes
7.3.9 Smoking Bans
7.3.10 Warning Information on Tobacco Products
7.3.11 Bans on Tobacco Advertising, Promotion and Sponsorship
7.4 Threats to the Smoking Cessation Industry
7.4.1 Concern over Side-Effects of Smoking Cessation Drugs
7.4.1.1 Champix/Chantix
7.4.1.2 Side-Effect Concerns for NRT and Bupropion
7.4.1.3 The Result of Side-Effect Concerns
7.4.2 Lack of Reimbursement for Smoking Cessation Therapies
7.4.3 Traditional Smokeless Tobacco
7.4.3.1 Snus and Gutkha
7.4.3.2 Possible Impact of Greater Smokeless Tobacco Use
7.4.4 The E-Cigarette
7.4.4.1 The E-Cigarette Market
7.4.4.2 Will E-Cigarettes Replace Smoking and Threaten the Smoking Cessation Drug Market?
7.4.4.3 E-Cigarettes and Smoking Cessation Therapies
8. RESEARCH INTERVIEWS
8.1 Interview with Dr Raafat Fahim, CEO, Nabi Biopharmaceuticals
8.1.1 Nicotine Vaccines
8.1.2 Smoking Cessation R&D Pipeline
8.1.3 Major Areas of Focus
8.1.4 Unmet Needs
8.1.5 Opportunities for Revenue Growth
8.2 Interview with Mr Trevor Van Meirlo, CEO, EvolutionNHS
8.2.1 Unmet Needs
8.2.2 Major Areas of Focus
8.2.3 Smoking Cessation R&D Pipeline
8.2.4 Opportunities for Revenue Growth
8.2.5 Market Drivers
8.3 Interview with Dr Peter Hajek, Director of Tobacco Dependence Research Unit, Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
8.3.1 Unmet Needs
8.3.2 Major Areas of Focus and R&D Pipeline
8.3.3 Opportunities for Revenue Growth
8.3.4 Market Drivers
9. CONCLUSIONS OF THE STUDY
9.1 Smoking is the Main Cause of Preventable Deaths Worldwide
9.2 Smoking Cessation Medicines Have Promising Therapeutic and Commercial Potential from 2012 to 2022
9.3 World Smoking Cessation Market: Prospects to 2022
9.4 Market Drivers
9.5 Leading and Emerging Smoking Cessation Markets
9.6 Concluding Remarks
LIST OF TABLES
Table 3.1 World Smoking Cessation Market Forecast ($bn), 2010-2022
Table 3.2 Smoking Cessation Market Forecasts ($bn): OTC and Rx Segments, 2010-2022
Table 3.3 Over-The-Counter Smoking Cessation Market Forecast ($bn), 2010-2022
Table 3.4 Prescription Smoking Cessation Market Forecast ($bn), 2010-2022
Table 3.5 Smoking Cessation Market Forecasts by Drug Type ($bn), 2010-2022
Table 3.6 Nicotine Replacement Therapy Market Forecast ($bn), 2010-2022
Table 3.7 Nicotine Receptor Partial Agonist Market Forecast ($bn), 2010-2022
Table 3.8 Antidepressants for Smoking Cessation: Market Forecast ($bn), 2010-2022
Table 4.1 Smoking Cessation Market Forecasts ($bn) for Leading Countries, 2010-2022
Table 4.2 Smoking Cessation Market by Leading Countries: Sales ($bn) & Market Shares (%), 2010
Table 4.3 US Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.4 Japanese Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.5 EU5 Smoking Cessation Market Forecasts ($bn), 2010-2022
Table 4.6 UK Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.7 French Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.8 Spanish Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.9 Italian Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.10 German Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.11 Chinese Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.12 Indian Smoking Cessation Market Forecast ($bn), 2010-2022
Table 5.1 Top 5 Smoking Cessation Drugs: Sales ($bn) and Market Shares (%), 2010
Table 5.2 Nicotine Replacement Therapy Types, 2012
Table 5.3 NiQuitin/Nicabate/NicoDerm CQ NRT Brands, 2012
Table 5.4 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($bn), 2010-2022
Table 5.5 Nicorette NRT Brands, 2012
Table 5.6 Nicorette Sales Forecast ($bn), 2010-2022
Table 5.7 Nicotinell Sales Forecast ($bn), 2010-2022
Table 5.8 Champix/Chantix Sales Forecast ($bn), 2010-2022
Table 5.9 Zyban Sales Forecast ($bn), 2010-2022
Table 5.10 Leading Smoking Cessation Brands: Sales Forecasts ($bn), 2010-2022
Table 6.1 Smoking Cessation R&D Pipeline: Some Leading Product Candidates, 2012
Table 7.1 SWOT Analysis of the Industry and Market, 2012-2022
Table 7.2 STEP Analysis of the Industry and Market, 2012-2022
Table 9.1 Smoking Cessation Drug Market by Leading Countries: Sales ($bn) and Market Shares (%), 2010, 2015 & 2022
Table 3.1 World Smoking Cessation Market Forecast ($bn), 2010-2022
Table 3.2 Smoking Cessation Market Forecasts ($bn): OTC and Rx Segments, 2010-2022
Table 3.3 Over-The-Counter Smoking Cessation Market Forecast ($bn), 2010-2022
Table 3.4 Prescription Smoking Cessation Market Forecast ($bn), 2010-2022
Table 3.5 Smoking Cessation Market Forecasts by Drug Type ($bn), 2010-2022
Table 3.6 Nicotine Replacement Therapy Market Forecast ($bn), 2010-2022
Table 3.7 Nicotine Receptor Partial Agonist Market Forecast ($bn), 2010-2022
Table 3.8 Antidepressants for Smoking Cessation: Market Forecast ($bn), 2010-2022
Table 4.1 Smoking Cessation Market Forecasts ($bn) for Leading Countries, 2010-2022
Table 4.2 Smoking Cessation Market by Leading Countries: Sales ($bn) & Market Shares (%), 2010
Table 4.3 US Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.4 Japanese Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.5 EU5 Smoking Cessation Market Forecasts ($bn), 2010-2022
Table 4.6 UK Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.7 French Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.8 Spanish Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.9 Italian Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.10 German Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.11 Chinese Smoking Cessation Market Forecast ($bn), 2010-2022
Table 4.12 Indian Smoking Cessation Market Forecast ($bn), 2010-2022
Table 5.1 Top 5 Smoking Cessation Drugs: Sales ($bn) and Market Shares (%), 2010
Table 5.2 Nicotine Replacement Therapy Types, 2012
Table 5.3 NiQuitin/Nicabate/NicoDerm CQ NRT Brands, 2012
Table 5.4 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($bn), 2010-2022
Table 5.5 Nicorette NRT Brands, 2012
Table 5.6 Nicorette Sales Forecast ($bn), 2010-2022
Table 5.7 Nicotinell Sales Forecast ($bn), 2010-2022
Table 5.8 Champix/Chantix Sales Forecast ($bn), 2010-2022
Table 5.9 Zyban Sales Forecast ($bn), 2010-2022
Table 5.10 Leading Smoking Cessation Brands: Sales Forecasts ($bn), 2010-2022
Table 6.1 Smoking Cessation R&D Pipeline: Some Leading Product Candidates, 2012
Table 7.1 SWOT Analysis of the Industry and Market, 2012-2022
Table 7.2 STEP Analysis of the Industry and Market, 2012-2022
Table 9.1 Smoking Cessation Drug Market by Leading Countries: Sales ($bn) and Market Shares (%), 2010, 2015 & 2022
LIST OF FIGURES
Figure 2.1 Smoking-Related Health Disorders
Figure 3.1 World Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 3.2 Smoking Cessation Market Shares (%) by Use, 2010
Figure 3.3 Over-The-Counter Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 3.4 Prescription Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 3.5 Smoking Cessation Market Share (%) by Drug Type, 2010
Figure 3.6 Nicotine Replacement Therapy Market Forecast ($bn), 2010-2022
Figure 3.7 Nicotine Receptor Partial Agonist Market Forecast ($bn), 2010-2022
Figure 3.8 Antidepressants for Smoking Cessation: Market Forecast ($bn), 2010-2022
Figure 4.1 Smoking Cessation Market Shares (%) by Leading Countries, 2010
Figure 4.2 Smoking Cessation Market Shares (%) by Leading Countries, 2015
Figure 4.3 Smoking Cessation Market Shares (%) by Leading Countries, 2022
Figure 4.4 US Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.5 Japanese Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.6 EU5 Smoking Cessation Market Forecasts ($bn), 2010-2022
Figure 4.7 UK Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.8 French Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.9 Spanish Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.10 Italian Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.11 German Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.12 Chinese Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.13 Indian Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 5.1 Top 5 Smoking Cessation Drugs: Market Shares (%), 2010
Figure 5.2 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($bn), 2010-2022
Figure 5.3 Nicorette Sales Forecast ($bn), 2010-2022
Figure 5.4 Nicotinell Sales Forecast ($bn), 2010-2022
Figure 5.5 Champix/Chantix Sales Forecast ($bn), 2010-2022
Figure 5.6 Zyban Sales Forecast ($bn), 2010-2022
Figure 9.1 Smoking Cessation Drugs: World Market Revenue Forecast ($bn), 2010-2022
Figure 9.2 Smoking Cessation Drug Market by Leading Countries: Market Shares (%), 2010, 2015 & 2022
COMPANIES LISTED
22nd Century Group
Action on Smoking on Health (ASH)
Alkermes
American Heart Association (AHA)
American Lung Association (ALA)
Aradigm
Australian Therapeutic Goods Administration
Barts and The London School of Medicine and Dentistry
Biovail
Boots
Ceejay Healthcare
Celtic Pharma
Centers for Disease Control and Prevention (CDC)
Cephalon
Chinese State Tobacco Monopoly Administration (STMA)
Cytos Biotechnology
Duke University
Embera NeuroTherapeutics
European Medicines Agency (EMA)
Evolution NHS
Evotec
Food and Drug Administration (FDA)
GlaxoSmithKline (GSK)
Health Canada
Independent Pharmaceutica AB
Japanese Ministry of Health, Labour and Welfare (MHLW)
Johnson & Johnson
Karolinska Institutet
LEO Pharma
LSU Health Sciences Center - Shreveport
Mayo Clinic
Medicines and Healthcare Products Regulatory Agency (MHRA)
Nabi Biopharmaceuticals
National Cancer Institute (NCI)
National Health Service (NHS)
National Institute for Health and Clinical Excellence (NICE)
National Institute on Drug Abuse (NIDA)
National Tobacco Corp (China)
Next Safety
Novartis
Nulife
Perrigo Company
Pfizer
Philip Morris Products S.A
Queen Mary University of London
R.J. Reynolds Tobacco Company
Roche
Rock Creek Pharmaceuticals
Ruyan
Sanofi
Selecta Biosciences
Sopharma
Star Scientific
Takeda
The Cochrane Collaboration
Tobacco Dependence Research Unit
Wolfson Institute of Preventive Medicine
World Health Organization (WHO)
Zenara
Figure 2.1 Smoking-Related Health Disorders
Figure 3.1 World Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 3.2 Smoking Cessation Market Shares (%) by Use, 2010
Figure 3.3 Over-The-Counter Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 3.4 Prescription Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 3.5 Smoking Cessation Market Share (%) by Drug Type, 2010
Figure 3.6 Nicotine Replacement Therapy Market Forecast ($bn), 2010-2022
Figure 3.7 Nicotine Receptor Partial Agonist Market Forecast ($bn), 2010-2022
Figure 3.8 Antidepressants for Smoking Cessation: Market Forecast ($bn), 2010-2022
Figure 4.1 Smoking Cessation Market Shares (%) by Leading Countries, 2010
Figure 4.2 Smoking Cessation Market Shares (%) by Leading Countries, 2015
Figure 4.3 Smoking Cessation Market Shares (%) by Leading Countries, 2022
Figure 4.4 US Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.5 Japanese Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.6 EU5 Smoking Cessation Market Forecasts ($bn), 2010-2022
Figure 4.7 UK Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.8 French Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.9 Spanish Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.10 Italian Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.11 German Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.12 Chinese Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 4.13 Indian Smoking Cessation Market Forecast ($bn), 2010-2022
Figure 5.1 Top 5 Smoking Cessation Drugs: Market Shares (%), 2010
Figure 5.2 NiQuitin/Nicabate/NicoDerm CQ Sales Forecast ($bn), 2010-2022
Figure 5.3 Nicorette Sales Forecast ($bn), 2010-2022
Figure 5.4 Nicotinell Sales Forecast ($bn), 2010-2022
Figure 5.5 Champix/Chantix Sales Forecast ($bn), 2010-2022
Figure 5.6 Zyban Sales Forecast ($bn), 2010-2022
Figure 9.1 Smoking Cessation Drugs: World Market Revenue Forecast ($bn), 2010-2022
Figure 9.2 Smoking Cessation Drug Market by Leading Countries: Market Shares (%), 2010, 2015 & 2022
COMPANIES LISTED
22nd Century Group
Action on Smoking on Health (ASH)
Alkermes
American Heart Association (AHA)
American Lung Association (ALA)
Aradigm
Australian Therapeutic Goods Administration
Barts and The London School of Medicine and Dentistry
Biovail
Boots
Ceejay Healthcare
Celtic Pharma
Centers for Disease Control and Prevention (CDC)
Cephalon
Chinese State Tobacco Monopoly Administration (STMA)
Cytos Biotechnology
Duke University
Embera NeuroTherapeutics
European Medicines Agency (EMA)
Evolution NHS
Evotec
Food and Drug Administration (FDA)
GlaxoSmithKline (GSK)
Health Canada
Independent Pharmaceutica AB
Japanese Ministry of Health, Labour and Welfare (MHLW)
Johnson & Johnson
Karolinska Institutet
LEO Pharma
LSU Health Sciences Center - Shreveport
Mayo Clinic
Medicines and Healthcare Products Regulatory Agency (MHRA)
Nabi Biopharmaceuticals
National Cancer Institute (NCI)
National Health Service (NHS)
National Institute for Health and Clinical Excellence (NICE)
National Institute on Drug Abuse (NIDA)
National Tobacco Corp (China)
Next Safety
Novartis
Nulife
Perrigo Company
Pfizer
Philip Morris Products S.A
Queen Mary University of London
R.J. Reynolds Tobacco Company
Roche
Rock Creek Pharmaceuticals
Ruyan
Sanofi
Selecta Biosciences
Sopharma
Star Scientific
Takeda
The Cochrane Collaboration
Tobacco Dependence Research Unit
Wolfson Institute of Preventive Medicine
World Health Organization (WHO)
Zenara
